Immunotherapy for Pediatric Malignancies

  E-mail   Print

Guest Editor
Michaela Semeraro
Clinical Investigation Center, Necker Children's Hospital, Paris, France
Email: michaela.semeraro@aphp.fr

Manuscript Topics
During the last years, the scientific and medical community has experienced a real revolution for the treatment of cancer thanks to the discoveries done in the field of the immunotherapy.

Immunotherapy-based approaches have proven to induce long-lasting clinical responses across multiple histological types of neoplasia, in previously difficult-to-treat adult cancers like high grade melanomas or lung cancers. These innovative treatments derive from a simple concept: treat cancer using our own defense system. Cancer treatment is now supposed to target not only the cancer cells but also the environment of the tumor and the immune system.

But where do we stand in Immunotherapy for pediatric cancers?

Until now, several studies have demonstrated an improvement of survival for children treated by integrating immune based therapy into standard multimodality regimens. This improvement concerns particularly pediatric patients with aggressive tumors that did not benefit from the significant progress in treatment made from the 1960s until about 2000 (i.e. metastatic sarcomas, Ewing tumors…).

A wide panel for immune-based therapies for pediatric cancer is now available in several countries based on already known immune treatments for adults, but also on combined strategies targeting specific pediatric cancer features. Nevertheless, pediatric cancer immunotherapies are not free from immune-related side effects and decreased efficacy over time. For these reasons, researchers and doctors are exploring the many roads to ensure that the immune system effectively attacks pediatric cancer cells.

This special issue will focus on
• immunotherapies developed and tested for solid and hematological pediatric cancers
• new immune strategies tailored for targeting high grade pediatric cancers
• useful and accessible biomarkers to follow the response to immunotherapy in children
• early and long-lasting immune-related side effects for children patients

Keywords: children, cancer, immunotherapy, monoclonal antibodies, CAR-T cells, cytokines, GD2, NK lymphocytes, toxicity, immune-suppression, antigens, vaccines.

Paper submission
All manuscripts will be peer-reviewed before their acceptance for publication.
The deadline for manuscript submission is August 30, 2019.

Instruction for Authors
http://aimspress.com/news/38.html
Please submit your manuscript to online submission system
http://www.aimspress.com/aimsmeds/ch/author/login.aspx

Catherine M. Albert, Seth Pollack
AIMS Medical Science, 2019, 6(3): 191-200. doi: 10.3934/medsci.2019.3.191
+ Abstract     + HTML     + PDF(128 KB)
Open Access Journals
Blog:
More
Open Access Journals